OUP user menu

Journal of Crohn's and Colitis: 9 (12)


Laurence J. Egan, Ireland

Associate Editors

Maria T. Abreu, USAShomron Ben-Horin, IsraelSilvio Danese, ItalyPeter Lakatos, HungaryMiles Parkes, UKGijs van den Brink, NLSéverine Vermeire, Belgium


Published on behalf of

Response to: Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy

Jeanne Tung, Felicity T. Enders, Edward V. Loftus Jr.
DOI: http://dx.doi.org/10.1016/j.crohns.2014.02.020 1327-1328 First published online: 1 October 2014
  • Monoclonal antibodies
  • Ulcerative colitis
  • Colectomy
  • Treatment outcome

Dear Sir,

We read with great interest the prospective observational study by Monterubbianesi et al. of infliximab (IFX) for the treatment of severe ulcerative colitis (UC)1. The authors noted 3- and 12-month colectomy rates of 18.6% and 25.6%, respectively. Three-dose induction was completed in 82%; importantly, 75% of those unable to complete induction required surgery. In multivariate analysis, high baseline CRP concentrations and severe endoscopic disease were associated with risk of colectomy. At our center, we also observed that patients who completed induction dosing fared better, irrespective of whether IFX was given in the inpatient or outpatient setting.

At our institution, we retrospectively observed …

Log in through your institution